Dosing a statin (rosuvastatin) every other day (EOD) may provide significant lipoprotein changes while avoiding common adverse effects in this statin-intolerant population. Objective: To determine ...
It also reported preliminary data with an oral triple agonist called retatrutide – targeting GLP-1, GIP, and glucagon – that is also being advanced quickly into phase 3. Shares in Pfizer fell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback